These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25016594)

  • 1. Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance.
    Putluri N; Maity S; Kommagani R; Creighton CJ; Putluri V; Chen F; Nanda S; Bhowmik SK; Terunuma A; Dorsey T; Nardone A; Fu X; Shaw C; Sarkar TR; Schiff R; Lydon JP; O'Malley BW; Ambs S; Das GM; Michailidis G; Sreekumar A
    Neoplasia; 2014 May; 16(5):390-402. PubMed ID: 25016594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.
    Shah KN; Wilson EA; Malla R; Elford HL; Faridi JS
    Mol Cancer Ther; 2015 Nov; 14(11):2411-21. PubMed ID: 26333382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
    Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
    Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired tamoxifen resistance is surmounted by GW8510 through ribonucleotide reductase M2 downregulation-mediated autophagy induction.
    Li ZN; Shu Y; Chen CG; Li XQ; Li MY; Zhao XH; Wang S; Li J
    Biochem Biophys Res Commun; 2020 Jul; 528(3):554-560. PubMed ID: 32505349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance.
    Abdel-Rahman MA; Mahfouz M; Habashy HO
    Diagn Pathol; 2022 Jan; 17(1):1. PubMed ID: 34986845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers.
    Zhang H; Liu X; Warden CD; Huang Y; Loera S; Xue L; Zhang S; Chu P; Zheng S; Yen Y
    BMC Cancer; 2014 Sep; 14():664. PubMed ID: 25213022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.
    Han P; Lin ZR; Xu LH; Zhong Q; Zhu XF; Liang FY; Cai Q; Huang XM; Zeng MS
    Mol Med Rep; 2015 Jul; 12(1):401-9. PubMed ID: 25695839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKT-induced tamoxifen resistance is overturned by RRM2 inhibition.
    Shah KN; Mehta KR; Peterson D; Evangelista M; Livesey JC; Faridi JS
    Mol Cancer Res; 2014 Mar; 12(3):394-407. PubMed ID: 24362250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
    Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
    Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioinformatics analysis revealing prognostic significance of
    Chen WX; Yang LG; Xu LY; Cheng L; Qian Q; Sun L; Zhu YL
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30898978
    [No Abstract]   [Full Text] [Related]  

  • 11. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
    Liu R; Guo CX; Zhou HH
    Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribonucleotide reductase subunit M2 is a potential prognostic marker and therapeutic target for soft tissue sarcoma.
    Das B; Jain N; Mallick B
    Gene; 2022 Jan; 808():145988. PubMed ID: 34624457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.
    Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R
    Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
    Mazzu YZ; Armenia J; Chakraborty G; Yoshikawa Y; Coggins SA; Nandakumar S; Gerke TA; Pomerantz MM; Qiu X; Zhao H; Atiq M; Khan N; Komura K; Lee GM; Fine SW; Bell C; O'Connor E; Long HW; Freedman ML; Kim B; Kantoff PW
    Clin Cancer Res; 2019 Jul; 25(14):4480-4492. PubMed ID: 30996073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
    Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
    Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors.
    Huang L; Zhao S; Frasor JM; Dai Y
    PLoS One; 2011; 6(7):e22274. PubMed ID: 21789246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling.
    Zhang X; Mu X; Huang O; Xie Z; Jiang M; Geng M; Shen K
    PLoS One; 2013; 8(8):e72053. PubMed ID: 23991038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.
    Liu X; Zhang H; Lai L; Wang X; Loera S; Xue L; He H; Zhang K; Hu S; Huang Y; Nelson RA; Zhou B; Zhou L; Chu P; Zhang S; Zheng S; Yen Y
    Clin Sci (Lond); 2013 May; 124(9):567-78. PubMed ID: 23113760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of catalytic subunit M2 in patients with ovarian cancer.
    Wang LM; Lu FF; Zhang SY; Yao RY; Xing XM; Wei ZM
    Chin Med J (Engl); 2012 Jun; 125(12):2151-6. PubMed ID: 22884145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.